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The high prevalence of sickle haemoglobin in Africa shows that malaria has been a major 
force for human evolutionary selection, but surprisingly few other polymorphisms have 
been proven to confer resistance to malaria in large epidemiological studies1-3.  To address 
this problem we conducted a multi-centre genome-wide association study (GWAS) of life-
threatening Plasmodium falciparum infection (severe malaria) in over 11,000 African 
children with replication data in a further 14,000 individuals.  Here we report a novel malaria 
resistance locus close to a cluster of genes encoding glycophorins that are receptors for 
erythrocyte invasion by P. falciparum.  We identify a haplotype at this locus which provides 
33% protection against severe malaria (OR=0.67, 95%CI=0.60-0.76, P=9.5x10-11) and is linked 
to polymorphisms previously shown to have features of ancient balancing selection, based 
on haplotype sharing between humans and chimpanzees4.  Taken together with previous 
observations on the malaria-protective role of blood group O1-3,5, these data reveal that two 
of the strongest GWAS signals for severe malaria lie in or close to genes encoding the 
glycosylated surface coat of the erythrocyte cell membrane, both within regions of the 
genome where it appears that evolution has maintained diversity for millions of years.  These 
findings provide new insights into the host-parasite interactions that are critical in 
determining the outcome of malaria infection. 
In the discovery phase of this study we analysed GWAS data on 5,633 children with severe 
malaria and 5,919 population controls from The Gambia, Kenya and Malawi, and in the 
replication phase we analysed candidate SNPs in a further 13,946 case control samples from 
Burkina Faso, Cameroon, The Gambia, Ghana, Malawi, Mali and Tanzania (Extended Data 
Figure 1).  The majority of samples used in the discovery phase have been analysed 
previously by lower resolution GWAS methods3. For this analysis we improved resolution by 
directly typing all samples at approximately 2.5 million SNPs using the Illumina Omni2.5M 
platform, followed by quality control (Extended Data Figures 1 and 2) and imputation of 
genotypes at over 10 million SNPs using haplotype data from the 1000 Genomes Project6. 
Imputation performance varied across populations, with accuracy decreasing as a function 
of the similarity between study and reference individuals (Extended Data Figure 3).  When 
testing for genetic association, principal components analysis was used to correct for 
population structure (Extended Data Figure 4a-e) which reflected both geography and self-
reported ethnicity. Similar results were obtained using a mixed-model approach (Extended 
Data Figure 4f). 
To assess the evidence for association in the discovery phase we used an approach which 
allows for heterogeneity in the protective effect of an allele across different study sites.  This 
could be particularly important in our data as high levels of genetic and ethnic diversity in 
Africa can result in variable patterns of linkage disequilibrium between study sites that can 
complicate GWAS analysis7.  Other potential sources of heterogeneity include allelic 
heterogeneity and multiple independent origins of malaria resistance loci, as has been well 
documented at the HBB locus1,3, as well as the high levels of genetic diversity in the 
parasite8. Specifically, we used a Bayesian approach that combines evidence across multiple 
models of association by specifying a prior probability on the size and similarity of genetic 
effect across populations, as well as the mode of inheritance1.  A single statistical summary 
of the signal of association was obtained by averaging the evidence across models, 
weighting each by its prior probability, and comparing the evidence to the null model of no 
association (model averaged Bayes factor; BFavg).  Having observed the data, a posterior 
probability was assigned to each model (Prmodel) conditional on it being a true association 
and the model assumptions, which are described in the Methods and Extended Data Figure 
5.   We replicated previously reported GWAS signals2,3,9 at the HBB (BFavg=5.8x1024), ABO 
(BFavg=6.7x109) and ATP2B4 (BFavg=4.4x105) loci, and a detailed analysis of key variants at 
these and other previously reported loci is presented elsewhere1.  A previously reported 
association near the gene MARVELD32 did not replicate in this dataset (Supplementary Note 
1).  Genome-wide patterns of association with severe malaria at the 34 regions of the 
genome containing a variant with either a Bayes factor for the most probable model (BFmax) 
> 2.5x104 or with a model averaged Bayes factor (BFavg) > 2.5x103 are summarised in 
Extended Data Figure 6 and Supplementary Table 1.  Details of the evidence for association 
in these regions can be viewed online at www.malariagen.net/resource/14.  
These data provide a rich resource of new candidate loci for further investigation.  Here we 
focus on a region of chromosome 4 shown in Figure 1, where the strongest signal of  
association (at SNP rs184895969) is located between the gene FREM3 and a cluster of three 
glycophorin genes (GYPE, GYPB and GYPA). Glycophorins are sialoglycoproteins that are 
abundantly expressed in the erythrocyte membrane, providing a hydrophilic surface coat 
that is necessary for erythrocytes to flow freely in the circulation. A complex system of 
single-nucleotide and structural variants in this region determine the MNS blood group 
system10.  These genes play a functional role in invasion of erythrocytes by P. falciparum.  
Glycophorin A is the receptor for the P. falciparum erythrocyte-binding ligand EBA-17511, 
and glycophorin B is a receptor for the parasite ligand EBL-112.  To follow up this observation, 
selected SNPs at this locus were genotyped by Sequenom iPLEX MassArray in the discovery 
and replication sample sets outlined above (Figure 1 and Extended Data Figure 7a).   The 
combined dataset of 25,498 samples provided convincing evidence of association at 
rs186873296 by standard fixed-effect meta-analysis (P = 9.5x10-11) as well as by the above 
Bayesian approach (BFoverall = 1.3x108; Figure 2 and Methods).  The minor allele frequency of 
rs186873296 was higher in East Africa than West Africa, and the greatest evidence of 
association was seen in Kenya where it was most common, with an allele frequency of 
approximately 10%.  Using only replication data to avoid winner’s curse, and assuming an 
additive model, we estimate that carrying one copy of the derived (non-ancestral) allele 
reduces the risk of severe malaria by about 40% in Kenya (OR = 0.60, 95% CI=0.46-0.79), 
with a slightly smaller effect across all populations (OR = 0.67, 95%CI 0.56-0.80 in frequentist 
fixed-effect meta-analysis).  Further details are given in Supplementary Note 2. 
The glycophorin gene cluster has a complex pattern of gene conversion and structural 
variation that has been previously noted; indeed it has been proposed that selective 
pressure due to pathogens, including malaria, has contributed to shaping diversity in this 
region10,13-16.  Using the human reference sequence and mapped sequence read data from 
the 1000 Genomes Project, we identified the boundaries of a 350kb region of sequence 
homology surrounding these genes as well as a set of segregating gene deletions (Extended 
Data Figure 8).  The lead imputed marker (rs184895969) is located within 10kb of this 
complex region. Imputation accuracy within the region is low using current reference data, 
so it is possible that the causal variant lies within the glycophorin genes themselves but that 
this is obscured in the current imputed dataset.  With this caveat, we computed a credible 
set of putatively causal variants in the region; this set includes both the lead imputed marker 
and a linked missense mutation (rs181620317) in FREM3 (Extended Data Figure 7b).  We 
note that the protective allele at rs184895969 was associated with increased GYPA 
transcription in published gene expression data for HapMap lymphoblastoid cell lines17 (P = 
0.016; Extended Data Figure 9); other regional analyses are described in Supplementary 
Notes 1-2.  Improved African genome variation reference panels7,18 are needed to 
understand the complex patterns of variation in this region so that the causal variant of 
malaria resistance can be fine-mapped with greater confidence. 
A striking feature of these data is that all of the loci which reach conventional criteria for 
genome-wide significance (P < 5x10-8 using a fixed effects model)  are in or near genes that 
play a key role in erythrocytes (HBB, ABO, ATP2B4, FREM3/GYPE), the primary host cell of P. 
falciparum.   Other erythrocyte-related genes are identified in the discovery phase analysis 
but do not reach genome-wide significance, including EPB41, which encodes erythrocyte 
membrane protein band 4.1 and has been implicated as a possible receptor for P. falciparum 
invasion19 (rs2985337: BFavg=3443; fixed-effect meta-analysis OR=1.16, 95%CI=1.09-1.23, 
P=1.2x10-6; see Extended Data Figure 6). 
An intriguing feature of the ABO locus is that it contains a number of polymorphisms that 
are shared between humans and other primates, and recent analyses of sequence variation 
across species indicated that some of these are ancient polymorphisms that have been 
maintained by balancing selection over millions of years20.  The current findings are of 
particular interest since the FREM3/GYPE is one of the most prominent examples of putative 
ancient balancing selection in a genome-wide analysis of haplotype sharing between 
humans and chimpanzees4. The peak GWAS signal at this locus is less than 45kb away from 
the shared human-chimp haplotype, which falls within the region covered by the credible 
set (Extended Data Figure 7b), although it does not exhibit a strong association with severe 
malaria (Supplementary Note 3).  To explore the genealogical relationship between the 
putative ancient balanced polymorphisms (ABPs) and SNPs associated with severe malaria in 
the FREM3/GYPE region, we inferred an ancestral tree21 from the African (YRI + LWK) part of 
the 1000 Genomes data and used it to order haplotypes in the region, labelled with the 
positions of ABPs, malaria-associated SNPs, and other variants of interest (Figure 3).  All 
three haplotypes carrying the protective allele at the directly-typed marker with most 
evidence of association (rs186873296) carry the minor allele at the ABP markers (D’=1, 
P=0.017).   By inferring the positions of putative causal mutations on the estimated 
genealogical tree21 at the lead imputed marker (rs184895969) we found evidence for a 
single protective mutation in Kenya (log10 BF=3.09; OR=0.6) estimated to lie on the branch 
ancestral to the protective allele at the lead marker. Although the most likely position for an 
additional mutation was on the branch ancestral to the ABPs, a single haplotype explains 
most of the signal of association in this region. 
These observations raise the question of whether malaria resistance loci are more likely to 
be found in regions of the genome that show evidence of ancient balancing selection.  We 
therefore analysed the relationship between the regions of association in our GWAS and 125 
regions of the genome found by Leffler et al4 to contain haplotypes shared between humans 
and chimpanzees. The SNPs defining these haplotypes (ABPs) were not themselves enriched 
for association with severe malaria (P > 0.1, Methods). We used a simulation approach to 
assess the physical proximity of ABPs to the peak of association within the 34 strongest 
regions of association (tier 1) and 73 weaker signals (tier 2), and observed a significant 
relationship with tier 1 over a range of length scales (Extended Data Figure 10a,d). We also 
identified the nearest gene to the lead marker within each association region as well as the 
gene nearest to each ABP haplotype, and performed a gene-based test for genome-wide 
enrichment.  Strong evidence for enrichment was seen at tier 1 loci (OR 41.0; P=4x10-7 by 
Fisher’s exact test, Psim=5x10-4 using a simulation approach described in Methods, and 
P=1x10-4 using the INRICH algorithm22; Extended Data Figures 10b-d) and a weaker trend at 
tier 2 loci (OR 7.7, Psim=0.15).  Apart from ABO and FREM3/GYPE, there were six other GWAS 
loci (4 in tier 1, 2 in tier 2) where the nearest gene to the lead marker was also the nearest 
gene to an ABP haplotype (DSCAM, NRG1, CNTNAP5, TMEM132C, CACNA2D1, RYR2).  
Although the current association evidence at these loci do not satisfy conventional criteria 
for genome-wide significance and they should be regarded as putative until convincingly 
replicated, it is noteworthy that they are all involved in key aspects of membrane biology 
(Supplementary Note 3).   
In the largest genetic association study of malaria to date, we have identified a new locus of 
resistance to severe malaria that lies next to a cluster of glycophorin genes involved in 
erythrocyte invasion by P. falciparum, and that also overlaps a locus of putative ancient 
balancing selection identified by analysis of haplotype sharing between humans and 
chimpanzees. It is possible that malaria is not the cause of the ancient balancing selection, 
or that it is just one of a number of opposing evolutionary driving forces, as at ABO, where 
blood group O reduces the risk of severe malaria but increases the risk of severe cholera23.  
Nonetheless, these new findings raise the intriguing question of whether natural selection 
on malaria susceptibility has been shaping genetic diversity in humans and their ancestors 
for millions of years.  P. falciparum is closely related to the chimpanzee parasite P. 
reichenowi and other parasites of African Great Apes24-26.  It has been proposed that P. 
falciparum was introduced into human populations from chimpanzees or gorillas in the 
recent past, but this remains a matter of intense debate25-27.  Population genetic data are 
consistent with an ancient origin followed by a marked expansion of the parasite population 
approximately ten thousand years ago, coincident with the introduction of agriculture28.  
The P. falciparum genome possesses a huge repertoire of polymorphism8 and it is possible 
that the host and parasite genomes are engaged in a longstanding evolutionary arms race, 
each maintaining diversity to try to outflank the other29. Intriguingly, the parasite surface 
receptor EBA-175, which directly binds glycophorin A during red cell invasion, also contains 
structural polymorphisms with features of ancient dimorphism30. The present findings 
provide new leads both to investigate these evolutionary mechanisms and to discover 




Figure 1: Signal of association with severe malaria across the FREM3/GYPE region.  a) 
evidence for association (log10 BFavg) in the discovery data.  Black plusses denote SNPs that 
were directly typed, and black triangles denote SNPs selected for typing on the Sequenom 
platform.  Dotted red vertical lines indicate a region of 0.25cM±25kb centred at the lead SNP 
(rs184895969).  Coloured circles denote the correlation (outer circles) and |D’| (inner 
circles) with rs184895969 in controls, computed from imputed haplotypes.  b) 
Polymorphisms shared between humans and chimpanzees, eQTLs, and previously reported 
associations with other phenotypes.  c,d) Genes in the region and the HapMap combined 
recombination rate. 
Figure 2: Evidence for association at SNPs in the FREM3/GYPE region assuming an additive 
model of association.  a) Forest plot showing sample size, estimated odds ratio and 95% 
confidence interval for the lead imputed SNP in each population and under fixed-effect 
meta-analysis.  The frequency of the protective allele in controls in each population is shown 
to the right. b) The posterior weight on different models of heterogeneity at rs184895969 
under the prior used in the GWAS.  Model names are described in Methods. c) Forest plot 
for the Sequenom-typed SNP rs186873296 in discovery and replication samples, with fixed-
effect meta-analysis across all populations and across East African populations (here taken 
as Kenya, Malawi, Tanzania and Cameroon.) 
Figure 3: Haplotype analysis across the FREM3/GYPE region. Left hand panel shows 
haplotypes at 7321 polymorphic SNPs between 144.5Mb and 145.2Mb on chromosome 4 in 
the LWK and YRI samples of the 1000 Genomes reference panel.  Key variants (Methods and 
Supplementary Note 2) are enlarged for clarity and labelled, with reference and non-
reference alleles coloured blue and yellow respectively. On the right is the estimated 
topology of the genealogical tree at rs184895969.  Dots indicate the position of the inferred 
protective mutation in Kenya and the branch ancestral to the ABPs, and are labelled with the 
estimated odds ratios (OR). 
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Samples, ethics and clinical information 
Samples were collected from nine partner projects from across sub-Saharan Africa 
(Extended Data Figure 1a) as described previously1,3. The studies and sample sets described 
in this manuscript form part of a larger ongoing project within the Malaria Genomic 
Epidemiology Network (www.malariagen.net).  We used the World Health Organisation 
definition of severe malaria which comprises a broad spectrum of life-threatening clinical 
complications of Plasmodium falciparum infection29,31.  Investigators from study sites 
worked together to agree on principles for sharing data and standardising clinical 
definitions, and to define best ethical practices across different local settings including the 
development of guidelines for informed consent.  Relevant ethics committees are listed in 
Extended Data Figure 1a.  Further information on policies, research and the consent process 
may be found on the MalariaGEN website (http://www.malariagen.net/community/ethics-
governance). 
DNA extraction and Sequenom typing 
As described previously1,3, all samples submitted to the MalariaGEN Resource Centre 
underwent a standard set of procedures that included quantification using picogreen, 
genotyping of 65 polymorphisms (including HbS - rs334, and 3 gender-typing SNPs) on the 
Sequenom iPLEX MassArray platform and matching to baseline clinical data (e.g. gender, 
ethnic group and case-control status). 
High-density genotyping  
Three cohorts (Gambia, Malawi and Kenya) were genotyped on the Illumina 
HumanOmni2.5-4 (Kenya) and Illumina HumanOmni2.5-8 (Gambia, Malawi) platforms. As 
described previously3 we used three different calling algorithms (Illuminus32, Illumina's 
Gencall algorithm as provided in BeadStudio, and GenoSNP33), each of which uses slightly 
different information in the data. We formed final genotype calls by taking consensus 
between the three algorithms. Genotypes where any two of the three calling algorithms 
were discordant, and genotypes where fewer than two algorithms were confident enough to 
make a call were treated as missing. This process showed improved calling, evaluated using 
Mendelian error counts in a subset of Kenyan samples, relative to each of the three 
algorithms separately (data not shown). 
Following genotype calling, we aligned genotypes to the forward strand of the human 
reference sequence (GRCh37), using both the Illumina-supplied manifest and publically 
available strand files (www.well.ox.ac.uk/~wrayner/strand) obtained by mapping allele 
probes to the reference by BLAT34. We removed SNPs whose position or strand mismatched 
between the Illumina manifest and the strand file. To simplify analyses, we restricted 
attention to the set of SNPs having the same name, chromosome, position, strand, and 
probe sequences across the two genotyping platforms.  Because the Omni2.5M contains 
multiple probes for some variants, we further removed SNPs to ensure positions were 
unique. In total we were left with 2322985 SNPs in each cohort across the autosomes and 
the X and Y chromosomes. We note that SNPs annotated as lying on the pseudo-autosomal 
region (PAR) of the X chromosome were not included, as these had position equal to 0 in the 
manifest for the HumanOmni2.5-4 array. Finally, we flipped alleles where necessary so that 
in downstream analyses the first allele always corresponds to the reference allele of the 
human genome sequence. 
Sample Quality Control 
We performed sample QC separately on each cohort by computing autosome-wide averages 
of normalised X channel intensity, normalised Y channel intensity, and heterozygosity and 
missingness based on the consensus call. To identify outlying samples we applied 
ABERRANT35, adjusting the lambda parameter per cohort to account for differences in 
genotyping quality (Extended Data Figure 1d-f).  In Gambia, a tail of samples showing low 
heterozygosity but otherwise appearing to be well typed was apparent. We explicitly 
included these samples in downstream analyses. 
To estimate genome-wide relatedness between samples, we selected a list of 178775 high 
quality SNPs satisfying the criteria missingness < 1%, MAF > 1% and thinned to be at least 
0.005cM apart and to have pairwise r2 < 0.3. Treating each cohort separately, we used 
SHELLFISH (www.stats.ox.ac.uk/~davison/software/shellfish/shellfish.php) to compute a 
matrix of pairwise relatedness values R = (rij) between samples, where rij denotes the 
genome-wide average covariance of frequency-normalised genotypes in individuals i and j.  
In samples with few close relationships, the value of rij can be thought of as an estimate of 
kinship36 with, for example, values close to 1 representing identity between samples, and 
values close to zero reflecting a lack of close relatedness (relative to the rest of the sample).  
To remove samples with duplicate typing and close relationships, we excluded one of each 
pair of samples with rij  > 0.2, taking all remaining samples through to phasing and 
imputation. Extended Data Figure 1c lists the number of samples before and after QC, and 
the number removed by each QC step; (*) denotes the number of samples removed after 
explicitly including samples with low heterozygosity in Gambia. 
We used SHELLFISH to compute principal components (PCs) on the post-QC sample set.  
Consistent with our removal of poor quality, duplicate and closely related samples, principal 
components plots show no substantially outlying samples (see Extended Data Figure 4a-c). 
The top few principal components in each cohort reflect substantial population structure, as 
evidenced by colouring by reported ethnicity. As found previously3,9, the top principal 
components are also significantly correlated with case-control status (Extended Data Figure 
4d), indicating that population structure may act as a confounding factor in association 
analyses if not controlled. 
Genotyping Quality Control 
Treating each cohort separately, we used SNPTEST 
(mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) to test for association at 
each autosomal SNP using a genotypic model of association which allows for different 
effects at heterozygote and homozygote genotypes, including the leading 5 principal 
components as covariates. Genotypic model association tests are particularly sensitive to 
confounding by genotyping error37, and we used the resulting P-values as a guide to finding 
appropriate QC criteria. To detect potential spurious genotypes due to batch effects, we 
modelled genotypes as predicted by the leading 5 principal components and case/control 
status in a linear regression framework in R38, and tested whether including an indicator of 
the plate on which each sample was genotyped contributed significantly to model fit.  We 
refer to this as the “Plate test”.  For downstream analyses we excluded SNPs with minor 
allele frequency < 1%, missing data proportion > 5% (in Gambia and Malawi) or > 2.5% (in 
Kenya, which had fewer missing genotypes overall), Hardy-Weinberg P < 1×10-20 in controls, 
or Plate-test P < 0.01. We inspected cluster plots of all remaining SNPs showing association 
test P < 1×10-5 (Gambia) or P < 1×10-4 (Kenya, Malawi) and excluded those with clear 
genotyping problems. Extended Data Figure 2a shows the number of SNPs excluded by each 
criterion. The post-exclusion genome-wide association analysis is shown in Extended Data 
Figure 2c. 
SNP QC on the X chromosome was performed as on the autosomes, with a few differences 
as follows. We treated males and females separately, using a genotypic model of association 
in females and an allelic model in males (who have only one copy of the X chromosome). 
Because genotype calling was performed blind to the gender of samples, some males appear 
to be heterozygous at some X chromosome SNPs. We treated all such heterozygous calls as 
missing. We computed missing data proportion and plate test P-values in males and females 
separately, and tested for departure from Hardy-Weinberg in female controls and for 
differences in frequency between males and females.  We excluded SNPs with MAF < 1%, 
missingness > 5% (Gambia, Malawi) or 2.5% (Kenya) in males or females, or plate test P < 
0.01 in males or females.  We further excluded SNPs with Hardy-Weinberg P < 1×10-20 in 
female controls or showing significant difference in allele frequencies between males and 
females (P < 1×10-20).  Extended Data Figure 2b shows the number of SNPs excluded by each 
criterion. 
Some regions of the X chromosome showed an elevated number of male heterozygote calls, 
contributing to the high number of SNPs excluded due to missingness in males. These 
included SNPs in the pseudo-autosomal regions at either end of the chromosome39 
(indicating that XY designation in the chip manifests does not adequately cover these 
regions) as well as SNPs within the X transposed region near the centromere. 
Phasing and imputation 
We phased genotype data in each cohort separately using SHAPEIT v2.r64440, specifying 200 
hidden states and an effective population size of 17469, as recommended for African 
populations by the SHAPEIT documentation, and phasing each chromosome separately.  We 
used IMPUTE v2.3.041,42 to impute phased genotypes into the 1000 Genomes6 Phase I 
integrated variant set (version of 24th August 2012, as downloaded from the IMPUTE 
website, which we refer to here as the 1000 Genomes reference panel) in 5Mb chunks with 
a buffer region of 500kb. For phasing and imputation we used the combined HapMap 
recombination map in build 37 coordinates included with the 1000 Genomes reference 
panel. Unless otherwise stated, downstream analyses included only SNPs with minor allele 
frequency > 0.5% and impute info metric > 0.75.  
Assessment of imputation 
At each genotyped SNP, IMPUTE computes squared correlation (referred to here as 
accuracy) and concordance between typed genotypes and genotypes obtained by masking 
the SNP and re-imputing.  To assess imputation performance, we plotted the cumulative 
distribution of concordance (Extended Data Figure 3a) and accuracy (Extended Data Figure 
3b), accuracy by frequency (Extended Data Figure 3d) as well as average per-sample 
accuracy (Extended Data Figure 3c). We also assessed accuracy relative to direct typing on 
the Sequenom platform at variants typed in the FREM3/GYPE, ARL14 and INPP4B regions of 
association as described below. 
Association testing and meta-analysis 
Association testing. We used SNPTEST to test for association at approximately 38 million 
variants obtained through imputation, including 5 PCs as covariates to control for population 
structure separately in each cohort. SNPTEST uses a missing data likelihood to account for 
the uncertainty in genotypes at imputed SNPs. We fit additive, dominant, recessive, and 
heterozygote models of association and ran SNPTEST separately in each imputation chunk.  
Below, we refer to the estimated effect size for population i and mode of inheritance m as 
βi,m and its estimated standard error as SEi,m. 
Frequentist meta-analysis. For each SNP and each mode of inheritance (additive, dominant, 
recessive, heterozygote) we computed the fixed-effect inverse variance-weighted meta-
analysis effect size, standard error, and P-value.  In this context, fixed-effect meta-analysis 
assumes a single true effect size which is identical between the three cohorts, and can be 
thought of as finding the maximum likelihood estimate of the effect size under the 
assumption that the likelihood in cohort i is proportional to the density of the normal 
distribution with mean βi,m and standard error SEi,m. 
Bayesian meta-analysis. We have previously1,3 used Bayesian meta-analysis techniques to 
allow for between-population heterogeneity of effect sizes in these three cohorts.  Here, we 
applied this method to compute Bayes factors for association under four modes of 
inheritance and six different models of correlation between cohorts.  In this framework, true 
effect sizes are modelled by a multivariate normal distribution centred on zero and with a 
given prior covariance matrix which can be written as σ2Ρ, where σ2 is a prior variance 
controlling the magnitude of plausible effects and Ρ is a prior correlation matrix.   
The correlation models we used were: 
Fixed effects (all elements of P equal to 1): as with frequentist fixed-effect meta-analysis, this 
assumes effect sizes are equal across the three cohorts.  
Correlated effects (all off-diagonal elements of P equal to 0.96): this assumes effect sizes are 
similar but allows for some variability. 
Independent effects (all off-diagonal elements of P equal to 0.1): this assumes there is little 
similarity between effect sizes in different cohorts. 
Structured effects We also considered models where effects in the two East African 
populations (Kenya and Malawi) were more similar to each other than to that in Gambia.  
We assumed either effects were fixed between Kenya and Malawi and correlated (ρ=0.96) 
between East Africa and Gambia (we refer to this as the fixed-structured-effect model), or 
that effects were correlated (ρ=0.96) between Kenya and Malawi and largely independent 
with Gambia (ρ=0.1) (referred to as the correlated-structured-effect model). 
We used prior variance parameters of σ2=0.22, reflecting a belief in relatively small effects 
(odds ratio < 1.5 with 95% probability)37, and σ2=0.752, reflecting a belief in larger effects 
(odds ratio < 4.5 with 95% probability). 
To form a single summary measure of evidence for association we formed a model-averaged 
Bayes factor (BF), referred to as the mean BF and denoted BFavg, as a weighted average of 
model-specific Bayes factors using the following weighting scheme.  We assigned weights of 
0.4 for additive mode of inheritance and 0.2 for dominant, recessive, or heterozygote modes 
of inheritance, reflecting a belief that variants which tag causal variants by LD are more likely 
to display additive effects.  We assigned a weight of 0.4, 0.2, and 0.1 to fixed-, correlated-, 
and independent-effect models, and 0.2 and 0.1 to fixed-structured and correlated-
structured effects models. Finally we assigned weight of 0.5 to small-effect models (σ2=0.22) 
and large-effect models (σ2=0.752).   Overall prior weights were assigned by multiplying 
across these categories; for example, the model representing small effect size distribution, 
fixed-effect across cohorts with additive mode of inheritance (denoted small-fix-add) was 
assigned prior weight equal to 0.5×0.4×0.4=0.08, while the model representing small, 
correlated-structured, dominant effects (denoted small-cor-str-dom) was assigned a prior 
weight of 0.5×0.1×0.2=0.01. For each SNP we also recorded the model having the highest 
posterior weight, and refer to its Bayes factor as the max BF (denoted BFmax).  Extended Data 
Figure 5a depicts slices through the combined prior on effect sizes across three cohorts for 
additive effect models.  The mean BF behaves similarly to a minimum over all four fixed-
effect meta-analysis P-values, but additionally captures effects that vary between cohorts 
(Extended Data Figure 5b). 
As described previously1,3, to computed model-specific Bayes factors efficiently we used an 
approximation of the likelihood by the density of a normal distribution with the estimated 
mean (βi,m) and standard error (SEi,m) in each cohort.  Thus, overall, observed effect sizes are 
modelled as normally distributed around zero with covariance that depends on the prior 
covariance in true effect sizes and on model standard errors,  
(βi,m) ~ N(0, σ2Ρ + V) 
where V is a diagonal matrix with ith diagonal entry equal to the squared standard error, 
SE2i,m.  The approximate or asymptotic Bayes factor can then be computed by evaluating a 
ratio of two normal densities.  In the univariate case this method is the same as described 
previously by Wakefield43.  To facilitate working with genome-wide meta-analysis results, we 
wrote custom software to compute frequentist and Bayesian meta-analyses, and stored 
details of genotype counts, association model fit, and meta-analysis results directly in a 
SQLite database file. 
Further discussion of the Bayesian approach can be found in Supplementary Note 4. 
X chromosome association testing and meta-analysis 
Association testing on the X chromosome was performed as for the autosomes with a few 
differences as follows.  We ran SNPTEST separately in males and females, estimating effect 
sizes under additive, dominant, recessive and heterozygote modes of inheritance in females.  
In this usage, SNPTEST assumes a model of complete inactivation so encodes male 
genotypes as 0/1 and females as 0/0.5/1 for an additive mode of inheritance.  We than 
meta-analysed the six gender-specific association analyses to produce frequentist fixed-
effect and model-averaged bayesian meta-analyses. 
For Bayesian analysis, in addition to summing over models of between-population 
heterogeneity, we adopted the view that differences in sex might lead to heterogeneity in 
effect.  We therefore included models of heterogeneity between males and females as 
follows.  Let ρsex denote the correlation between effects in male and female samples within a 
single population.  We included models where males and females have the same effect 
(ρsex=1, termed fixed-sex model and given prior weight 0.45), correlated effects (ρsex=0.96, 
termed correlated-sex model and given prior weight 0.225) or essentially independent 
effects (ρsex=0.1, termed independent-sex model and given prior weight 0.225).  Because 
some parts of the X chromosome escape inactivation39,44, we also included a model where 
the effect in females is twice that in males (given prior weight 0.1). 
To fully specify prior correlation for each model, for each pair of populations A,B we also 
need to specify the correlation (denoted ρcross) between males in A and females in B.  We set 
ρcross =ρpop × ρsex where ρpop  is the chosen prior correlation between same-sex samples in A 
and B (i.e. ρpop =1, 0.96 or 0.1 as defined above). 
As above, we formed overall weights by multiplying across categories, so that for example 
the model of small, additive effects that are fixed across populations and across sexes 
(denoted small-fixsex-fix-add) had prior weight 0.5x0.4x0.4x0.45=0.036. 
Linear mixed model analysis 
To compare association test results for logistic regression as implemented in SNPTEST with 
the use of a linear mixed model, we reran association test scans in each discovery cohort 
using the program MMM45.  We used the same genome-wide relatedness matrix as used to 
compute principal components (see above) and assumed an additive model of association.  
We plotted the –log10( P-value ) for MMM against the corresponding –log10( P-value ) 
based on the SNPTEST scan (which used 5 PCs as described above), for each discovery 
population and for fixed-effect meta-analysis (Extended Data Figure 4f).  P-values under 
both methods at tier 1 loci are listed in Supplementary Table 1. 
Lead SNPs, region and tier definitions 
We formed a list of lead SNPs within approximately independent regions of interest as 
follows.  We restricted to variants with IMPUTE info measure at least 0.75 across all three 
populations and ranked variants by the model-averaged Bayes factor (highest to lowest).  
We iteratively picked lead SNPs from the top of the list and excluded other variants within a 
recombination interval of 0.25cM±25kb centred at the lead SNP (referred to below as the 
association region), continuing until no more SNPs remained with BFavg>250 or BFmax>2500. 
 
We grouped lead SNPs into two tiers as follows: 
• tier 1: all lead SNPs with BFavg>2500 or BFmax>25000 
• tier 2: all lead SNPs not in tier 1 with BFavg>1000 or BFmax>10000 
In total, across the autosomes and the X chromosome there were 34 regions in tier 1 and 73 
in tier 2, with association regions covering approximately 13Mb and 26Mb of the genome 
respectively. 
Regional association analysis 
For each tier 1 and 2 region, we examined the pattern of association in the region, 
generating a regional association plot for the region annotated with details of the meta-
analysis for the lead SNP as follows. 
LD computation. In each region we computed pairwise LD statistics between the lead SNP 
and surrounding SNPs using best-guess imputed haplotypes for control samples across three 
populations.  To facilitate this computation, we stored imputed haplotypes in a SQLite-
format database allowing us effective random access to haplotype data.  We used R to 
compute both Pearson correlation coefficient (r2) and Lewontin’s |D’| between the lead SNP 
and all other SNPs in the region.  
Regional association plot. For each SNP in tier 1 and 2 we plotted log10(BFavg) in the 
association region around the lead SNP plus 1Mb on either side, colouring points according 
to LD, with outer circles representing r2 and inner circles representing |D’|.  We further 
annotated SNPs that were typed in at least one cohort (using black plusses) and SNPs that 
had Sequenom genotype data available (with black triangles). 
Regional annotations. We plotted all ABP variants (Supplementary Tables 4 and 5 of Leffler 
et al4), eQTLs from the Genotype-Tissue Expression project46 (GTEx), and previously 
reported47 GWAS loci.  Where SNPs matched an imputed or typed variant, we computed LD 
statistics and coloured these points as above. We plotted all RefSeq genes (as downloaded 
from the UCSC Genome Browser MySQL database48 on 2013-03-18) in the region, annotating 
the direction of transcription.  We further plotted local recombination rate estimates from 
the HapMap combined recombination map included with the IMPUTE haplotypes described 
above. 
Meta-analysis. We annotated plots with effect sizes and confidence intervals for the lead 
SNP for each mode of inheritance (additive, dominant, recessive and heterozygote) that 
informed the model averaging.  We also produced barplots showing the posterior 
distribution on models of association using the prior weights described above.  
Cluster plots. Finally, for each region, we produced and inspected cluster plots for all typed 
SNPs with BFavg >= 10 that were not excluded by QC. As phasing fills in missing genotypes 
and potentially improves genotype calling based on LD with surrounding SNPs, we coloured 
plots based on genotype calls taken from the output of phasing. 
Website. Regional association plots and cluster plots can be viewed online at 
http://www.malariagen.net/resource/14. 
Validation and replication typing 
Based on a preliminary version of the data presented here we selected SNPs for typing on 
the Sequenom platform across the whole MalariaGEN Consortial Project 1 sample set, which 
includes the discovery samples, further cases and controls in the same populations that 
were not included in the GWAS, and further large sample sets from five other populations 
from sub-Saharan Africa (see Extended Data Figure 1a).  Data were available for SNPs 
tagging the lead markers in the FREM3/GYPE, INPP4B and ARL14 regions (r2>0.5 in controls, 
as estimated using the EM algorithm) as well as other regions not represented in tier 1.  
Replication analysis 
Replication analysis using Sequenom data was restricted to the set of samples with less than 
10% missingness as measured across the set of 70 SNPs chosen for replication typing.  In 
each population we conducted logistic regression in R, including five principal components 
(discovery samples) or reported ethnicity (replication samples) as covariates to control for 
population structure.  For each GWAS lead SNP, we examined each Sequenom SNP in the 
region and computed r2 and |D’| with the lead SNP.  To allow for the effects of incomplete 
LD on the Bayesian model fitting, we recomputed the Bayesian analysis in the discovery 
samples based on Sequenom genotypes at each SNP, to obtain a Sequenom-based mean 
Bayes factor and a ‘best model’ Bayes factor at the model with highest posterior weight.  
Where LD is incomplete or where imputation is imperfect, this model may differ from the 
best model for imputed data. 
For each SNP we computed fixed-effect meta-analysis across discovery samples, across 
replication samples, and across all samples.   We also computed the Bayes factor for 
replication samples (BFreplication) for the model with highest posterior weight in the discovery 
samples.   To compute an overall Bayes factor for association, we combined the discovery 
BFavg computed at the imputed lead marker with the replication bayes factor at the 
Sequenom SNP, as BFoverall =  BFavg x BFreplication.  We use the imputed lead marker here 
because the number of discovery samples directly typed was smaller than the number of 
imputed samples.  Conditional on the lead imputed and replication markers reflecting the 
same signal of association, this BFoverall represents an overall measure of the evidence for 
association at the locus that reflects all the samples in our study. 
A discussion of the replication evidence in the FREM3/GYPE, INPP4B and ARL14 regions can 
be found in Supplementary Note 1. 
MalariaGEN encourages individual study sites to perform more detailed analyses of local 
patterns of disease association, and a Tanzanian-focused analysis of FREM3 and other 
candidate SNPs that were genotyped as part of this study is reported elsewhere49.  
Credible interval analysis 
In a given region of the genome, under the assumption that exactly one variant (that is 
accessible to our typing or imputation) is causal, the posterior probability that each variant is 
the causal variant can be computed by a simple reweighting of Bayes factors50.  Using this 
approach we computed 95% and 99% credible intervals (i.e. the smallest set of SNPs 
accounting for 95% or 99% of the posterior mass) for variants in the association region 
around rs184895969, plus a margin of 50kb at either end (Extended Data Figure 7b).  We 
noted that rs181620317, which is annotated as a missense mutation for the gene FREM3, is 
within the 95% confidence interval in our data.  We note that while this analysis is simple 
and appealing, its interpretation depends on assumptions about the true disease model, and 
on the behaviour of imputation in the region50; in particular the difficulty of imputing 
variants around the three glycophorin genes (Extended Data Figure 8) might make this 
analysis fail to capture putatively important variation within or around GYPA, GYPB, or GYPE. 
Sequence homology and alignability in the glycophorin region 
To investigate the location of our GWAS signal with respect to the pattern of sequence 
homology around the three glycophorin genes, we generated a dot plot (Extended Data 
Figure 8a) showing co-occurrence of k-mers in the human reference sequence51 in the 
region.  Considerable sequence homology was observed over a region of about 350kb 
covering the three genes.  Our lead GWAS marker and the ABPs lie just outside this region.  
The high level of homology should affect our ability to align probes or sequences to this part 
of the genome.  To confirm this, we also plotted the UCSC alignability track (‘CRG alignability 
100’, Extended Data Figure 8c), which shows the degree to which the 100-mer starting at 
each position in the reference sequence is alignable (with a value of 1/n indicating that the 
100-mer aligns to n positions across the genome, allowing up to two mismatches).  As 
expected, even short regions of shared kmers affect alignability considerably, with 
alignability dropping to an average of about 0.7 within the large region of homology.  
Similarly, we plotted imputation performance (as measured by the IMPUTE info score) and 
observed a marked drop within the region of sequence homology. 
Structural variation in the glycophorin region 
We attempted to identify structural variation in the glycophorin region by examining 
sequence read data generated by the 1000 Genomes’ project, using the set of BAM files 
available from the 1000G project in October 2014, downloaded from 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data.  These data contain a mixture of read 
lengths, with most reads of at least 90bp and some reads of 76bp.  We considered only 
reads with mappinq quality at least 20.  For each sample we computed coverage across the 
glycophorin region, normalised by average coverage computed across chromosome 1, and 
refer to these values here as ‘coverage’. 
Coverage values across the region were correlated with genome alignability (as defined 
above), with coverage dropping substantially in regions of low alignability.  We therefore 
restricted attention to the set of perfectly alignable positions, here defined as positions such 
that every 100-mer overlapping the position in the reference sequence aligns uniquely, 
allowing up to two mismatches (and computed using the CRG alignability 100 track 
described above).  As expected, coverage at perfectly alignable positions showed little or 
none of the variation present in genome alignability (Extended Data Figure 8e-g). 
Two large structural variants, present at frequencies of at least 1% in LWK+YRI, were evident 
in coverage data.  Genotypes for both these variants were called by the 1000 Genomes 
phase I and are referred to as esv2668125 (also called MERGED_DEL_2_26708) and 
esv2662558 (also called MERGED_DEL_2_26722).  Both deletions putatively represent 
deletions of all or part of GYPB.  We noted some uncertainty as to the location of the 
breakpoints of both deletions - with 1000 Genomes’ breakpoints differing from the 
breakpoints as they appeared in coverage data by at least 10kb.  We further noted that 
three samples (NA18519, NA19185, NA19222) that were called as heterozygote for one or 
both deletions by the 1000 Genomes project, appeared to have homozygous genotypes 
(red, blue and green lines, Extended Data Figure 8e-g). 
Expression QTL analysis 
To investigate the effect of associated SNPs in the FREM3 region on expression of nearby 
genes, we downloaded publically available data on RNA expression levels17 in HapMap 
samples, and plotted expression levels of genes in the region (Figure 1) against genotypes at 
the lead SNP and other SNPs of interest in African samples (YRI+LWK, Extended Data Figure 
9).  Data was available for genes INPP4B, USP38, GAB1, SMARCA5, GYPE, GYPB, GYPA, HHIP, 
ANAPC10 and ABCE1, with three probes available for GYPE, two for GAB1 and one probe for 
each of the other genes.  Five samples in this dataset (NA19318, NA19324, NA19377, 
NA19429, NA19190) carry the protective allele at the lead marker rs184895969, while only 
two carry the protective allele at the directly-typed rs186873296.  For each gene and SNP 
we tested for a trend of genotype on expression using linear regression. Extended Data 9 
shows all probes for the glycophorins as well as other regional genes for which a P-value less 
than 0.05 was observed. 
GENECLUSTER analysis 
We used the program TREESIM21 to estimate an ancestral recombination graph for the LWK 
and YRI individuals in the 1000 Genomes Project haplotype data in a region from 144.6Mb to 
144.8Mb on chromosome 4 centred on the lead SNP in the FREM3 / GYPE region. We then 
ran GENECLUSTER21 in the region, allowing it to assign either one or two causal mutations in 
each marginal genealogy.  GENECLUSTER works by probabilistically assigning study 
individuals to the tips of the tree estimated by TREESIM, and attempts to explain 
case/control status by assigning causal mutations to the branches of the tree in a Bayesian 
framework.  This analysis is somewhat similar in spirit to our marginal SNP analysis, but has 
important differences.  In particular, GENECLUSTER may detect associated mutations 
anywhere on the tree (which may not correspond directly to any typed or imputed variant), 
and can assess models of association involving more than a single causal variant.  However, 
GENECLUSTER does not take into account principal components or otherwise control for 
population structure, and for computational reasons we only included the Luhyan (LWK) and 
Yoruban (YRI) populations from the 1000 Genomes reference panel in the analysis. 
To investigate the relationship between ancestry and variants of interest, we plotted 
IMPUTE reference panel haplotypes in the region ordered by the marginal tree at the 
position of the imputed lead marker (rs184895969), annotating the lead imputed and 
Sequenom-typed markers, ABPs, previously reported GYPE eQTLs52, common deletions, and 
variants determining the M/N and S/s blood groups as described in Supplementary Note 2 
(Figure 3). 
Analysis of enrichment of malaria-associated loci in functional categories 
Full details of enrichment analyses are provided in Supplementary Note 3. 
 
Code availability 
The SNPTEST software for genome-wide association testing is available at 
https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html. 
Executables and source code for inthinnerator are available at 
http://www.well.ox.ac.uk/~gav/inthinnerator. 
Further software for generating key results for this paper will be made available at 
http://www.malariagen.net/resource/14. 
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Extended Data Figure Legends 
Extended Data Figure 1: Sample collections included in the study.  a) Study sites and ethics 
approving institutions.  b) Phenotypic makeup of discovery and replication samples from 
each site. ‘UNCOMPLICATED’ refers to case individuals who were not identified as cerebral 
malaria (CM) or severe malarial anaemia (SMA) cases.  ‘BOTH” refers to individuals who 
have both CM and SMA phenotypes.  c) Overall sample counts and number of samples 
excluded by each QC criterion.  (*) denotes the number of samples removed after explicitly 
including samples with low heterozygosity in Gambia.  (†) The Kenyan cohort included 
parents of a subset of case samples; these were not used in subsequent analyses.  d) Plots of 
average genome-wide heterozygosity and missingness with outliers coloured, as output by 
the ABERRANT algorithm. 
Extended Data Figure 2: Genotyped SNP quality control (QC) for the 3 discovery cohorts.  
a,b) Total numbers of pre- and post-QC SNPs on a) the autosomes and b) the X 
chromosome, and numbers of SNPs excluded by each QC criteria.  MAF refers to minor allele 
frequency, HWE to Hardy-Weinberg equilibrium, Plate to the plate test of association and 
Diff. to the test of difference in frequency between males and females.  Details of QC are 
given in Methods.   c) Plot showing the –log10(P values) for the genotypic association test in 
the discovery data including the first 5 principal components as covariates.  Grey dots show 
SNPs that are removed due to the QC as defined in Methods. The total fraction of SNPs 
removed from each cohort is given at the top of the plot. 
Extended Data Figure 3: Imputation performance.  a,b) Empirical distribution of 
concordance and accuracy (r2) between typed and re-imputed SNPs in the three discovery 
cohorts.  Solid lines represent SNPs with frequency below 5% and dashed lines represent 
SNPs with frequency of at least 5%.  c) Per-sample concordance and accuracy (type 0 r2) 
across the whole genome, as estimated by reimputing genotyped SNPs.  Values are 
averaged over imputation chunks.  d) Average accuracy between genotype and re-imputed 
SNPs in each cohort, plotted against frequency, in 1% frequency bins.  
Extended Data Figure 4: Top ten principal components (PCs) in a) Gambia, b) Malawi and c) 
Kenya.  Where ethnicity was reported, points are coloured by ethnicity for ethnicities with at 
least 50 samples.  d) Logistic regression P-values and direction of effect for the top ten 
principal components on Severe Malaria status in each cohort. e) qq-plots for additive model 
association test P-values in Gambia, Malawi, Kenya, and for fixed-effect meta-analysis. 
Dashed lines represent the 99% confidence interval computed marginally at each variant.  
Circles and points represent points lying respectively outside and inside the 99% confidence 
interval.  f) Comparison of association test P-values for logistic regression (SNPTEST, x-axis) 
and linear mixed model (MMM, y-axis) for Gambia, Malawi, Kenya, and for fixed-effect 
meta-analysis.  Variants in tier 1 are coloured blue, with the lead marker at the FREM3/GYPE 
region coloured red. 
Extended Data Figure 5: Detail of Bayesian analysis of discovery cohorts.  a) Visualisation of 
slices through the combined prior on effect sizes in three cohorts for mode-of-inheritance-
specific models.  Top row: slices through the prior effect size on Kenya (x-axis) and Malawi 
(y-axis) for constant effect size in Gambia (panels).  Bottom row: slices through the prior 
effect size on Kenya (x-axis) and Gambia (y-axis) for constant effect size in Malawi (panels).  
Red lines represent a factor of 10 in the prior density. b) Comparison of BFavg (x-axis) with 
the minimum fixed-effect meta-analysis P-value minimized across additive, dominant, 
recessive or heterozygote modes of inheritance (y-axis).  Values are plotted on log10 and –
log10 scales. Colour indicates the heterogeneity model of the model with the highest 
posterior weight. c) Sensitivity of BFavg to changes in prior.  Plots show BFavg ratio (y-axis) 
plotted against one-dimensional parameterisations of the prior (x-axis), for the 32 
autosomal SNPs in tier 1. Solid lines represent variants with minor allele frequency < 5% 
averaged across populations, and dashed lines variants with minor allele frequency >= 5%.  
Black dots indicate the lead marker at the FREM3/GYPE locus. Colour indicates the effect 
size, mode of inheritance, or heterogeneity model for the model with highest posterior 
weight under the GWAS prior.  Dashed grey vertical lines indicate the x-axis value 
corresponding to the prior used in the GWAS, and one-half and twice that value.  Plots are 
parameterised by i) the prior standard deviation of the small-effect model keeping the prior 
standard deviation of the large and small-effect models in the ratio 0.75:0.2; ii-v) the prior 
weight on additive, dominant, recessive or heterozygote modes of inheritance; vi-x) the 
prior weight on fixed, correlated, independent, fixed-structured and correlated-structured 
models.  For each parameterisation prior weights on other models are kept in the same 
relative proportion.  For further details see Supplementary Note 4. 
Extended Data Figure 6: Strongest regions of association in the Bayesian analysis of the 
three discovery cohorts.  Plot on left shows the log10 model- averaged Bayes Factor (BFavg). 
Table shows the SNP with the highest BFavg in each region (lead SNP), gene(s) of interest in 
the region, the model with the highest posterior weight at the lead SNP and its BF. Coloured 
points indicate the odds ratio (OR) and the protective allele frequency in Gambia (red), 
Malawi (green) and Kenya (Blue). The right hand columns indicate regions containing shared 
chimp-human haplotypes or coding SNPs4 (ABPs), blood group genes, or Immunoglobulin 
superfamily genes. 
Extended Data Figure 7: a) Evidence for association at directly-typed SNPs in the 
FREM3/GYPE, INPP4B and ARL14 regions.  b) Posterior probability that variants in the 
FREM3/GYPE region are causal assuming a single variant in the region is causal50, based on 
the BFavg for typed and imputed variants.  Dashed lines indicate the 95% and 99% credible 
sets.  See Figure 1 legend for further details.  c) Details of SNPs encoding the common MNS 
blood groups.  Coordinates and alleles are with respect to the NCBI b37 human reference 
sequence.  d) Evidence for possible independence of effects at the FREM3 and INPP4B loci in 
Kenya by conditional analysis.  Y-axis represents -log10(association P-value) conditional on 
the imputed dosage at rs184895969.  Points are coloured by LD with the top SNP 
rs13103597.  e) Forest plot showing sample size, estimated odds ratio and 95% confidence 
interval for the lead imputed SNP (rs149373719) in INPP4B under an additive model of 
association. f) Bar plot showing the posterior weight on different models of heterogeneity at 
rs149373719 under the prior used in the GWAS, assuming an additive model of association.  
g) Forest plot showing evidence in both discovery and replication samples in the Sequenom 
data at rs77389579 in INPP4B.  See Figure 2 legend for further details. 
Extended Data Figure 8: Sequence homology, alignability and structural variation in the 
glycophorin region.  a) co-occurrence of 100-mers (upper triangle) and 25-mers (lower 
triangle) in the human reference sequence.  Each point represents a kmer that maps to the 
locations indicated by the x and y axis positions, either on the same strand (black points) or 
opposite strands (red points).  Green vertical lines in this and subsequent panels delineate 
the region of high homology surrounding the three glycophorins.  b) the location of the lead 
GWAS marker, ABPs, and protein-coding genes in the region.  c) alignability of the 100-mer 
at each position of the reference, up to two mismatches. Values are taken from the UCSC 
genome browser mappability track and averaged over 5kb bins.  d) IMPUTE info in Kenya for 
variants with frequency at least 5%, averaged over 5kb bins. e-f) coverage for samples from 
YRI and LWK in 1000G Phase 1 carrying esv2662558, carrying esv2668125, or not carrying 
either deletion, respectively. Coverage for each individual is normalised by the mean 
coverage for that individual across chromosome 1, and only computed at positions with 
alignability = 1 for all 100-mers overlapping the position, and for reads with mapping quality 
at least 20.  Values are averaged over 5kb (grey) and 10kb (blue) bins.  Three samples with 
apparently erroneous calls in the 1000G Phase1 genotype release are coloured (NA18519, 
red; NA19185, yellow; NA19222, green) and assigned to the status indicated by their 
coverage profile.  The bottom row represents a sample of 30 individuals not carrying the 
deletion selected at random in addition to the two with erroneous genotype calls. Coverage 
computation was performed using the BAM files available from the 1000G project in 
October 2014, downloaded from ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data.  Four 
African samples in the Phase 1 release were not assessed because they are not included in 
this directory.  
Extended Data Figure 9: Correlation between the genotypes at SNPs of interest within the 
GYPE/A/B locus and reported gene transcription levels in samples from the YRI and LWK 
HapMap cohorts17.  P values are for a trend test of association where more than one 
genotype class is present.  Only assays targeting the glycophorins, and those with a P-value 
below 0.05 are shown. 
Extended Data Figure 10: Detail of enrichment analysis.  a) Red histogram: the empirical 
distribution of the log10 distance of observed tier 1 loci to the nearest ABP haplotype.  Grey 
histogram: distribution of distances for 10,000 simulated tier 1 sets. b) The log10 distance of 
tier 1 (filled red circles) and tier 2 (empty circles) loci to the nearest ABP, plotted against 
their rank in BFavg order (stronger signals have lower rank). Loci are annotated with the 
nearest gene where a gene exists within the association region.  Asterisks denote nearest 
genes that are also the nearest gene to an ABP shared haplotype. c) Empirical null 
distribution of the odds ratio for the enrichment of tier 1 loci in the set of genes closest to an 
ABP shared haplotype, based on 10,000 simulated SNP sets.  The red asterisk and text 
indicate the odds ratio for the observed tier 1 loci. d) Distribution of the proportion of the 
genome which identifies a given gene as nearest, for genes in or not in the set annotated as 
nearest an ABP haplotype.  Left: distribution of the length of the genome for which the given 
gene is unambiguously the closest gene.  Middle: distribution of the number of SNPs in our 
study for which the given gene is the closest gene.  Right: distribution of the number of SNPs 
in our study for which the given gene is the nearest gene within a recombination interval of 
2.5cM±25kb around the SNP, as used to determine nearest genes to GWAS lead SNPs.  e) 
Empirical P-values for enrichment of ABP haplotypes and coding SNPs in tier 1 and tier 2 
GWAS regions.  Second column: P-values for enrichment by gene overlap.  Third to tenth 
column: P-values for enrichment by proximity at different length scales.  †Results for 
simulations using SNPs frequency-matched to GWAS tier 1 loci in 1% frequency bins. 
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1. Assessment	  of	  association	  evidence	  in	  specific	  regions	  
Replication	  evidence	  in	  the	  FREM3/GYPE	  region	  
In	  the	  FREM3/GYPE	  region	  we	  typed	  several	  SNPs	  including	  the	  lead	  imputed	  marker	  
rs184895969	  on	  the	  Sequenom	  platform	  (Figure	  1,	  Extended	  Data	  Figure	  7a).	  	  However,	  
agreement	  between	  the	  Sequenom	  and	  best-­‐guess	  imputed	  genotypes	  at	  this	  SNP	  was	  poor	  
(r2<0.1,	  estimated	  using	  EM	  algorithm)	  both	  across	  three	  cohorts	  and	  in	  East	  African	  
populations,	  where	  the	  frequency	  is	  highest.	  	  The	  best	  Sequenom	  markers	  by	  r2	  were	  
rs186873296	  (r2=0.932),	  rs186790584	  (r2=0.943)	  and	  rs149914432	  (r2=0.87).	  	  	  Replication	  
evidence	  at	  these	  three	  SNPs	  was	  similar	  and	  is	  presented	  in	  Figure	  2	  and	  Extended	  Data	  
Figure	  7a.	  	  
Association	  with	  severe	  malaria	  subtypes	  in	  the	  FREM3/GYPE	  region	  
To	  estimate	  the	  effect	  of	  the	  association	  in	  the	  FREM3/GYPE	  region	  on	  clinical	  subtypes	  of	  
severe	  malaria,	  we	  fit	  a	  logistic	  regression	  model	  for	  cerebral	  malaria	  (CM)	  versus	  controls	  
and	  for	  severe	  malarial	  anaemia	  (SMA)	  versus	  controls	  using	  Sequenom	  data	  for	  
rs186873296	  across	  discovery	  and	  replication	  samples	  in	  Kenya,	  including	  ethnicity	  as	  a	  
covariate	  to	  control	  for	  population	  structure.	  	  In	  total	  there	  were	  4118	  controls,	  659	  CM	  
cases	  and	  263	  SMA	  cases	  in	  Kenya,	  of	  which	  136	  cases	  were	  classified	  as	  both	  CM	  and	  SMA.	  	  
A	  further	  944	  cases	  were	  not	  classified	  as	  either	  CM	  or	  SMA	  and	  were	  not	  used	  to	  estimate	  
subtype-­‐specific	  effects.	  
Evidence	  for	  association	  in	  INPP4B	  
We	  investigated	  the	  evidence	  for	  association	  at	  a	  second	  peak	  of	  association	  (rs149373719)	  
located	  approximately	  1Mb	  away	  from	  the	  lead	  marker	  in	  the	  FREM3/GYPE	  region	  (see	  
Figure	  1).	  	  Discovery	  phase	  evidence	  for	  association	  at	  this	  SNP	  was	  driven	  largely	  by	  Kenya,	  
where	  a	  strong	  effect	  was	  observed,	  but	  an	  opposite	  direction	  of	  effect	  was	  observed	  in	  
Malawi	  (Extended	  Data	  Figure	  7e).	  	  Replication	  evidence	  at	  the	  directly-­‐typed	  marker	  
rs77389579	  was	  more	  consistent	  across	  East	  African	  populations,	  but	  with	  little	  evidence	  in	  
central	  or	  western	  Africa	  (Extended	  Data	  Figure	  7g)	  where	  the	  frequency	  was	  low.	  
To	  determine	  if	  this	  signal	  was	  driven	  by	  LD	  with	  the	  lead	  imputed	  marker	  at	  the	  
FREM3/GYPE	  region,	  we	  conducted	  association	  analysis	  in	  the	  region	  conditional	  on	  the	  
additive	  dosage	  at	  rs184895969	  in	  Kenya.	  	  SNPs	  in	  INPP4B	  remained	  associated	  (P<1x10-­‐4	  at	  
rs13103597,	  Extended	  Data	  Figure	  7d),	  suggesting	  that	  this	  association	  may	  be	  somewhat	  
independent	  of	  the	  FREM3/GYPE	  association	  signal.	  
Replication	  evidence	  in	  the	  ARL14	  region	  
We	  observed	  a	  strong	  signal	  of	  association	  in	  discovery	  populations	  near	  the	  gene	  ARL14	  
(rs74954675,	  BFavg=7.8x104,	  OR=1.34,	  95%	  CI	  1.21-­‐1.49,	  P=5.1x10-­‐8	  in	  fixed-­‐effect	  meta-­‐
analysis	  for	  dominant	  model;	  see	  Extended	  Data	  Figure	  6).	  	  We	  directly	  typed	  rs74954675	  
and	  two	  other	  regional	  SNPs	  on	  the	  Sequenom	  platform,	  with	  genotypes	  showing	  good	  
agreement	  with	  best-­‐guess	  imputed	  genotypes	  (r2=0.94	  between	  Sequenom-­‐typed	  and	  best-­‐
guess	  imputed	  genotypes	  in	  discovery	  populations	  at	  rs74954675;	  Extended	  Data	  Figure	  7a).	  	  
However,	  replication	  evidence	  was	  poor	  (one-­‐sided	  fixed-­‐effect	  P	  >	  0.5),	  with	  no	  replication	  
population	  showing	  strong	  evidence,	  and	  the	  effect	  estimated	  as	  protective	  in	  three	  of	  
seven	  replication	  populations.	  
3	  
	  
We	  note	  that	  the	  lack	  of	  a	  genome-­‐wide	  control	  for	  population	  structure	  in	  replication	  
populations,	  as	  well	  as	  potential	  phenotypic	  differences	  between	  discovery	  and	  replication	  
sets	  (see	  Extended	  Data	  Figure	  1b)	  may	  impede	  our	  ability	  to	  replicate	  signals	  of	  association.	  
Evidence	  for	  association	  at	  MARVELD3	  
We	  examined	  evidence	  for	  association	  at	  rs2334880,	  previously	  reported	  as	  associated	  with	  
severe	  malaria	  in	  a	  population	  from	  Ghana1,	  in	  our	  discovery	  data	  but	  saw	  no	  evidence	  of	  
association	  at	  this	  SNP	  (BFavg	  =	  0.12,	  P	  >	  0.18	  in	  fixed-­‐effect	  meta-­‐analysis	  or	  population-­‐
specific	  analyses)	  or	  for	  other	  SNPs	  in	  the	  region	  (BFavg	  <	  20	  for	  SNPs	  within	  500kb).	  	  A	  
regional	  association	  plot	  detailing	  the	  evidence	  in	  this	  region	  can	  be	  found	  at	  
http://www.malariagen.net/resource/14.	  
	  
2. Analysis	  of	  putative	  functional	  and	  structural	  variants	  in	  the	  FREM3/GYPE	  
region	  
Determination	  of	  MNS	  blood	  group	  variants	  
We	  used	  dbRBC2	  and	  the	  Ensembl	  Genome	  Browser3	  to	  identify	  mutations	  encoding	  the	  
MNS	  blood	  group	  antigens,	  cross-­‐checking	  with	  previously	  published	  protein/sequence	  
alignments4.	  	  The	  M/N	  blood	  groups	  are	  encoded	  by	  three	  SNPs	  in	  the	  20th	  and	  24th	  amino	  
acid	  encoded	  by	  GYPA,	  which	  is	  transcribed	  on	  the	  reverse	  strand	  of	  the	  human	  reference	  
sequence.	  	  Comparison	  with	  the	  cDNA	  and	  reference	  sequence	  of	  the	  major	  GYPA	  transcript	  
in	  Ensembl	  identifies	  these	  as	  rs7658293,	  rs7687256	  and	  rs7687256	  (Extended	  Data	  Figure	  
7c).	  	  The	  human	  reference	  sequence	  encodes	  Glutamine	  and	  Leucine	  at	  these	  codons	  and	  
hence	  the	  N	  blood	  group.	  	  Of	  these	  SNPs,	  only	  one	  (rs7687256)	  was	  present	  in	  the	  1000	  
Genomes	  reference	  panel.	  
The	  S/s	  blood	  groups	  are	  encoded	  by	  a	  single	  SNP	  in	  the	  48th	  amino	  acid	  of	  GYPB,	  which	  is	  
also	  transcribed	  on	  the	  reverse	  strand	  of	  the	  human	  reference	  sequence.	  	  As	  above	  we	  
inspected	  the	  cDNA	  sequence	  of	  the	  major	  transcript	  of	  GYPB	  to	  identify	  this	  SNP	  as	  
rs7683365,	  also	  present	  in	  the	  1000	  Genomes	  reference	  panel.	  	  At	  this	  amino	  acid,	  the	  
human	  reference	  sequence	  encodes	  Threonine	  and	  hence	  the	  s	  blood	  group	  (Extended	  Data	  
Figure	  7c).	  
Reimputation	  of	  large	  structural	  variants	  
To	  improve	  imputation	  of	  the	  deletions	  esv2668125	  and	  esv2662558	  (see	  Methods),	  we	  
generated	  a	  custom	  reference	  panel	  for	  each	  deletion	  in	  the	  region	  140-­‐145Mb	  on	  
chromosome	  4,	  plus	  a	  margin	  of	  500kb	  at	  either	  end.	  	  These	  panels	  differed	  from	  the	  
original	  panel	  in	  two	  ways.	  	  Firstly,	  we	  corrected	  the	  haplotypes	  for	  three	  individuals	  
NA18519,	  NA19185,	  NA19222	  based	  on	  examination	  of	  the	  underlying	  read	  data,	  as	  
described	  in	  Methods	  and	  Extended	  Data	  Figure	  8e-­‐g.	  	  Secondly,	  because	  neither	  the	  1000	  
Genomes	  pipeline	  nor	  our	  genotype	  calling	  took	  into	  account	  ploidy	  within	  large	  structural	  
variants	  such	  as	  these,	  typed	  variants	  within	  the	  deletions	  could	  lead	  to	  spurious	  imputation.	  	  
To	  avoid	  this,	  for	  each	  deletion	  we	  removed	  all	  variants	  within	  the	  deletion	  breakpoints	  from	  
the	  modified	  panel.	  
Reimputed	  calls	  for	  esv2668125,	  which	  was	  imputed	  with	  high	  confidence	  in	  the	  discovery	  
imputation	  (IMPUTE	  info>0.93),	  showed	  good	  agreement	  with	  the	  original	  calls	  (r2=0.98,	  
4	  
	  
concordance	  =	  0.99	  for	  the	  genotype	  with	  highest	  imputation	  probability;	  non-­‐reference	  
allele	  frequency	  =	  5%	  across	  populations).	  
Deletion	  esv2662558	  was	  reimputed	  with	  higher	  confidence	  (IMPUTE	  info	  >	  0.59)	  than	  in	  the	  
discovery	  scan	  (IMPUTE	  info	  <	  0.4).	  	  Reimputed	  calls	  showed	  low	  correlation	  (r2=0.13,	  
concordance	  =	  0.97)	  and	  an	  increase	  in	  allele	  frequency	  (2.1%	  versus	  1.7%)	  relative	  to	  the	  
discovery	  imputation.	  
Association	  analysis	  with	  regional	  variants	  
To	  investigate	  the	  association	  signal	  within	  the	  FREM3/GYPE	  region,	  we	  fit	  association	  
models	  including	  the	  lead	  imputed	  marker	  (rs184895969)	  or	  the	  Sequenom-­‐typed	  lead	  
marker	  (rs186873296),	  and	  a	  set	  of	  potentially	  functional	  variants,	  including	  the	  ABPs	  
(represented	  by	  rs67600034),	  reported	  regional	  eQTLs5	  (including	  rs1822841	  and	  
rs11100806),	  large	  deletions	  (esv2662558	  and	  esv2668125	  based	  on	  re-­‐imputation	  as	  
described	  above),	  the	  FREM3	  missense	  mutation	  that	  is	  within	  the	  95%	  confidence	  interval	  
in	  our	  data	  (rs181620317),	  a	  SNP	  tagging	  the	  N/M	  blood	  group	  (rs7687256),	  and	  a	  SNP	  
tagging	  the	  S/s	  blood	  group	  (rs7683365).	  	  We	  used	  logistic	  regression	  in	  R	  to	  test	  whether	  
the	  putatively	  functional	  variants	  jointly	  improved	  model	  fit	  relative	  to	  the	  null	  model,	  which	  
included	  5	  PCs	  and	  either	  the	  lead	  imputed	  marker	  rs184895969	  or	  the	  Sequenom-­‐typed	  
rs186873296	  included	  as	  an	  additive	  effect.	  	  We	  observed	  no	  significant	  improvement	  in	  
model	  fit	  (likelihood	  ratio	  test	  P>0.05),	  either	  across	  all	  samples	  or	  within	  each	  population.	  
To	  investigate	  whether	  specific	  haplotypes	  might	  better	  explain	  observed	  patterns	  of	  risk,	  
we	  included	  all	  haplotypes	  having	  frequency	  at	  least	  1%	  at	  the	  above	  variants,	  based	  on	  
best-­‐guess	  haplotypes	  from	  imputation,	  in	  a	  joint	  model	  of	  association	  and	  asked	  whether	  
the	  haplotypes	  improved	  model	  fit	  relative	  to	  the	  model	  including	  only	  the	  lead	  marker.	  	  We	  
observed	  no	  evidence	  that	  haplotypes	  explained	  additional	  association	  signal	  (P>0.1)	  either	  
across	  all	  samples	  or	  within	  each	  population.	  	  
For	  each	  variant,	  we	  also	  tested	  whether	  including	  the	  variant	  marginally	  under	  an	  additive,	  
dominant,	  recessive	  or	  heterozygote	  model	  improved	  model	  fit.	  	  In	  Malawi,	  we	  saw	  
nominally	  significant	  evidence	  for	  a	  protective	  effect	  of	  non-­‐reference	  alleles	  at	  the	  two	  
SNPs	  rs67600034	  and	  rs11100806,	  which	  are	  in	  LD	  (r2=0.93	  in	  YRI+LWK),	  with	  the	  highest	  
evidence	  for	  a	  recessive	  protective	  effect	  of	  the	  non-­‐reference	  allele	  (P=0.005	  at	  
rs11100806).	  	  However,	  effects	  were	  inconsistent	  across	  populations,	  with	  the	  same	  allele	  
estimated	  has	  having	  a	  mild	  risk	  effect	  in	  Kenya.	  
We	  also	  tested	  for	  interactions	  of	  each	  variant	  with	  the	  lead	  FREM3/GYPE	  marker	  and	  noted	  
nominally	  significant	  interactions	  of	  rs186873296	  with	  rs7683365	  (P=0.004),	  though	  this	  
effect	  was	  less	  pronounced	  when	  testing	  with	  the	  imputed	  rs184895969,	  and	  with	  the	  GYPE	  
eQTL	  rs7686794	  (P=0.006),	  in	  Gambia.	  	  No	  variant	  showed	  evidence	  for	  a	  conditional	  or	  
interaction	  effect	  across	  all	  populations	  (P>0.01).	  
GENECLUSTER	  analysis	  
We	  ran	  GENECLUSTER6	  as	  described	  in	  Methods.	  	  In	  Kenya,	  using	  the	  TREESIM	  tree	  inferred	  
at	  the	  position	  of	  the	  lead	  marker	  (rs184895969),	  GENECLUSTER	  placed	  a	  mutation	  
subtending	  all	  haplotypes	  carrying	  the	  risk	  allele	  with	  log10(BF)	  =	  3.09	  (OR	  =	  0.6;	  Figure	  3).	  
Allowing	  for	  a	  second	  mutation	  defines	  three	  classes	  of	  haplotype	  risk	  and	  marginally	  
increased	  the	  evidence	  for	  association	  log10(BF)	  =	  3.23.	  The	  second	  mutation	  defines	  a	  sub-­‐
tree	  which	  tags	  the	  ABP	  haplotype	  and	  had	  marginally	  increased	  risk	  (OR	  =	  1.01).	  In	  Gambia	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and	  Malawi,	  the	  same	  branch	  of	  the	  tree	  was	  inferred	  as	  the	  location	  of	  the	  best	  single	  
mutation,	  but	  with	  no	  evidence	  of	  association	  (BF	  <	  1)	  and	  decreased	  odds	  ratios	  (OR	  =	  0.98	  
and	  0.88	  respectively).	  We	  observed	  considerable	  variation	  between	  estimated	  marginal	  
trees	  in	  the	  region.	  	  In	  Kenya,	  the	  position	  with	  the	  highest	  posterior	  was	  at	  144694105	  with	  
log10(BF)=4.4	  under	  the	  two-­‐mutation	  model.	  
	  
3. Analysis	  of	  enrichment	  of	  malaria-­‐associated	  loci	  in	  functional	  categories	  
Gene-­‐based	  enrichment	  analysis	  
We	  tested	  for	  enrichment	  of	  our	  tier	  1	  and	  tier	  2	  regions	  in	  predefined	  collections	  of	  
functionally	  related	  genes	  as	  follows.	  We	  tested	  for	  enrichment	  in	  four	  broad	  sets	  of	  genes:	  
	  
1. HUGO	  Gene	  families.	  	  These	  were	  downloaded	  from	  the	  HUGO	  Gene	  Nomenclature	  
Committee	  website.	  	  A	  total	  of	  560	  gene	  sets	  were	  used.	  
2. Custom	  gene	  sets.	  	  We	  also	  included	  two	  sets	  of	  genes	  previously	  listed	  as	  nearest	  to	  
putative	  ancient	  balancing	  polymorphisms	  (Leffler	  et	  al7,	  Supplementary	  Table	  S4	  
and	  S5),	  treating	  shared	  coding	  SNPs	  and	  shared	  haplotypes	  separately,	  and	  also	  
formed	  the	  combined	  set	  of	  genes	  in	  the	  ISET	  and	  VSET	  HUGO	  Gene	  families	  as	  
single	  ISET/VSET	  gene	  set.	  
3. Gene	  Ontology	  (GO)	  terms.	  	  We	  downloaded	  the	  “latest-­‐lite”	  database	  dated	  2013-­‐
11-­‐23	  from	  www.geneontology.org	  and	  used	  a	  SQL	  query	  to	  extract	  a	  transitive	  list	  
of	  members	  of	  each	  gene	  family.	  	  A	  total	  of	  17718	  GO	  terms	  were	  included.	  
4. Sets	  of	  genes	  previously	  identified	  as	  associated	  with	  red	  blood	  cell	  traits8.	  
We	  aimed	  to	  test	  for	  enrichment	  of	  these	  gene	  sets	  in	  the	  list	  of	  genes	  nearest	  to	  our	  lead	  
SNPs	  in	  each	  tier.	  	  To	  form	  this	  list,	  we	  considered	  all	  RefSeq	  genes	  (downloaded	  from	  the	  
UCSC	  Genome	  Browser	  MySQL	  database9	  on	  2013-­‐03-­‐18).	  	  For	  each	  of	  our	  tier	  1	  and	  tier	  2	  
regions,	  we	  determined	  the	  nearest	  gene	  to	  the	  lead	  SNP	  by	  physical	  distance,	  including	  only	  
genes	  which	  intersected	  the	  association	  region,	  and	  considering	  all	  possible	  transcripts	  
where	  several	  transcripts	  existed	  for	  a	  gene.	  
For	  each	  gene	  set	  we	  computed	  an	  odds	  ratio	  (OR)	  by	  forming	  the	  2x2	  table	  
	  
	  
In	  gene	  set	   Not	  in	  gene	  set	  
In	  GWAS	  association	  
region	  
a	   b	  
Not	  in	  GWAS	  
association	  region	  
c	   d	  
where	  a,	  b,	  c	  and	  d	  represent	  the	  counts	  of	  genes	  in	  the	  given	  categories,	  and	  computing	  the	  
odds	  ratio	  as	  OR=ad/bc.	  	  To	  do	  so,	  it	  is	  necessary	  to	  specify	  a	  ‘universe’	  set	  containing	  all	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genes	  that	  appear	  in	  the	  table	  (i.e.	  containing	  a	  total	  of	  a+b+c+d	  genes).	  	  For	  most	  analyses	  
we	  took	  the	  universe	  to	  consist	  of	  all	  RefSeq	  genes	  that	  lie	  on	  the	  autosomes	  and	  the	  X	  
chromosome	  (23584	  genes	  in	  total),	  while	  for	  Gene	  Ontology	  analyses	  we	  further	  restricted	  
to	  genes	  annotated	  to	  at	  least	  one	  GO	  term	  (17708	  genes).	  
Fisher’s	  exact	  test	  can	  be	  used	  to	  test	  the	  hypothesis	  OR=1.	  	  However,	  Fisher’s	  exact	  test	  
assumes	  an	  underlying	  model	  of	  binomial	  sampling	  in	  each	  row	  of	  the	  table,	  which	  is	  
inappropriate	  here	  because	  some	  genes	  are	  more	  likely	  to	  be	  the	  nearest	  gene	  to	  a	  GWAS	  
lead	  marker	  by	  chance.	  	  In	  particular	  this	  is	  true	  of	  the	  set	  of	  genes	  closest	  to	  ABP	  
haplotypes,	  which	  is	  enriched	  for	  genes	  covering	  an	  unusually	  large	  proportion	  of	  the	  
genome	  (as	  measured	  by	  the	  size	  of	  the	  of	  the	  genome	  or	  the	  number	  of	  SNPs	  in	  our	  study	  
for	  which	  the	  gene	  is	  the	  closest	  gene;	  see	  Extended	  Data	  Figure	  10d).	  	  To	  assess	  enrichment	  
we	  therefore	  adopted	  a	  simulation	  scheme.	  
We	  simulated	  10,000	  sets	  of	  tier	  1	  lead	  SNPs	  by	  iteratively	  picking	  SNPs	  uniformly	  from	  the	  
set	  of	  SNPs	  included	  in	  the	  GWAS	  analysis	  and,	  as	  for	  the	  GWAS	  SNPs,	  excluding	  other	  SNPs	  
within	  a	  region	  of	  2.5cM±25kb	  centred	  at	  the	  chosen	  SNP,	  to	  form	  a	  list	  of	  34	  SNPs.	  	  For	  
each	  set	  of	  simulated	  SNPs	  we	  computed	  odds	  ratios	  as	  above	  and	  computed	  an	  empirical	  P-­‐
value,	  denoted	  Psim,	  as	  the	  proportion	  of	  odds	  ratios	  as	  large	  or	  larger	  than	  that	  observed	  for	  
the	  true	  data.	  	  These	  P-­‐values	  thus	  reflect	  the	  null	  model	  in	  which	  each	  SNP	  included	  in	  our	  
study	  has	  equal	  probability	  of	  being	  a	  lead	  SNP.	  
Potentially,	  SNPs	  close	  to	  or	  in	  LD	  with	  ABPs	  might	  have	  a	  frequency	  distribution	  that	  differs	  
from	  the	  genome-­‐wide	  distribution,	  affecting	  the	  power	  of	  our	  study	  at	  these	  SNPs.	  	  We	  
therefore	  conducted	  further	  simulations	  matching	  the	  frequency	  of	  picked	  SNPs	  to	  the	  
frequency	  of	  SNPs	  in	  GWAS	  tier	  1.	  	  Specifically,	  we	  computed	  the	  1%	  frequency	  bin	  of	  each	  
GWAS	  tier	  1	  SNP	  in	  controls	  across	  all	  cohorts.	  For	  each	  simulated	  set	  we	  then	  picked	  the	  ith	  
SNP	  from	  the	  set	  of	  SNPs	  having	  the	  same	  frequency	  bin	  as	  the	  ith	  GWAS	  SNP	  (taken	  in	  
order	  of	  decreasing	  BFavg).	  
Simulations	  for	  tier	  2	  were	  conducted	  as	  for	  tier	  1	  except	  that	  we	  excluded	  all	  SNPs	  in	  the	  
GWAS	  tier	  1	  regions	  from	  the	  simulation,	  and	  any	  gene	  intersecting	  the	  GWAS	  tier	  1	  regions	  
from	  the	  counts	  forming	  the	  2x2	  table.	  	  For	  the	  list	  of	  genes	  nearest	  to	  true	  GWAS	  tier	  2	  hits,	  
this	  removed	  gene	  PAX5	  which	  also	  overlaps	  the	  tier	  1	  region	  near	  ZCCHC7.	  	  To	  assess	  the	  
extent	  to	  which	  enrichment	  in	  tier	  1	  is	  driven	  by	  the	  previously	  identified	  loci	  and	  the	  new	  
FREM3	  locus,	  we	  also	  conducted	  additional	  tier	  1	  simulations	  removing	  regions	  of	  HBB,	  ABO,	  
ATP2B4,	  FREM3,	  INPP4B	  and	  HHIP.	  
All	  simulations	  were	  conducted	  using	  the	  program	  inthinnerator,	  available	  at	  
http://www.well.ox.ac.uk/~gav/inthinnerator.	  	  Empirical	  P-­‐values	  for	  all	  tier	  1	  and	  tier	  2	  
simulations	  are	  shown	  in	  Extended	  Data	  Figure	  10e.	  
Distance-­‐based	  enrichment	  analysis	  
Using	  the	  same	  set	  of	  simulated	  SNP	  sets	  we	  also	  evaluated	  enrichment	  of	  ABP	  haplotypes	  
and	  coding	  SNPs	  within	  different	  length	  scales	  of	  GWAS	  lead	  SNPs.	  	  For	  each	  distance	  50kb,	  
100kb,	  250kb,	  500kb,	  750kb,	  1Mb,	  2.5Mb,	  5Mb	  and	  10Mb	  we	  computed	  an	  indicator	  
variable	  encoding	  whether	  an	  ABP	  occurred	  within	  the	  given	  distance	  of	  each	  lead	  SNP	  in	  
the	  GWAS	  set	  and	  each	  simulated	  set.	  We	  computed	  empirical	  P-­‐values	  (again	  denoted	  Psim)	  
as	  the	  proportion	  of	  simulations	  for	  which	  the	  number	  of	  regions	  containing	  an	  ABP	  within	  
the	  given	  distance	  was	  greater	  than	  or	  equal	  to	  the	  number	  for	  the	  GWAS	  set.	  	  Empirical	  P-­‐
values	  for	  SNPs	  in	  tier	  1	  and	  2	  are	  shown	  in	  Extended	  Data	  Figure	  10e.	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Overlap	  between	  genes	  nearest	  to	  ABPs	  and	  to	  GWAS	  loci	  
Apart	  from	  ABO	  and	  FREM3/GYPE,	  we	  find	  six	  other	  putative	  signals	  of	  association	  with	  
severe	  malaria	  (4	  in	  tier	  1,	  2	  in	  tier	  2)	  where	  the	  nearest	  gene	  to	  the	  GWAS	  peak	  is	  also	  the	  
nearest	  gene	  to	  an	  ABP.	  	  DSCAM	  is	  a	  member	  of	  the	  immunoglobulin	  superfamily	  whose	  
Anopheles	  gambiae	  orthologue	  plays	  a	  role	  in	  innate	  immune	  recognition	  of	  Plasmodium	  
falciparum10.	  	  NRG1	  is	  a	  glycoprotein	  with	  diverse	  signalling	  properties	  and	  a	  great	  variety	  of	  
isoforms	  that	  include	  immunoglobulin	  I-­‐set	  and	  epidermal	  growth	  factor-­‐like	  domains.	  	  
CNTNAP5	  belongs	  to	  a	  family	  of	  cell	  adhesion	  and	  receptor	  proteins.	  	  TMEM132C	  encodes	  a	  
transmembrane	  protein	  of	  unknown	  function.	  CACNA2D1	  and	  RYR2	  are	  both	  part	  of	  calcium	  
channel	  complexes	  which	  is	  interesting	  in	  view	  of	  the	  importance	  of	  calcium	  signalling	  in	  
host	  cell	  invasion	  and	  the	  known	  association	  with	  ATP2B41	  which	  encodes	  the	  main	  
erythrocyte	  calcium	  channel.	  
	  
4. Interpretation	  and	  sensitivity	  of	  the	  model-­‐averaged	  Bayes	  factor	  
Interpretation	  of	  the	  Bayes	  factor	  
Overall	  evidence	  for	  association	  is	  measured	  by	  the	  posterior	  probability	  for	  association,	  
which	  takes	  into	  account	  both	  the	  Bayes	  factor	  and	  the	  prior	  odds	  of	  association:	  
(Posterior	  odds	  that	  variant	  is	  associated)	  =	  BF	  x	  (prior	  odds	  that	  variant	  is	  associated)	  
For	  GWAS	  studies,	  a	  value	  of	  1	  in	  100,000	  for	  prior	  odds,	  based	  on	  assumptions	  about	  the	  
number	  of	  loci	  plausibly	  involved	  in	  disease	  susceptibility	  and	  the	  extent	  of	  LD	  surrounding	  
the	  associated	  variants,	  has	  commonly	  been	  used11,12.	  	  For	  the	  lead	  marker	  in	  the	  
FREM3/GYPE	  region	  this	  gives	  a	  posterior	  odds	  of	  association	  of	  0.156	  and	  a	  posterior	  
probability	  of	  13.5%	  using	  the	  BFavg	  computed	  in	  discovery	  samples,	  and	  a	  posterior	  
probability	  of	  almost	  100%	  using	  the	  Bayes	  factor	  computed	  across	  discovery	  and	  replication	  
samples,	  while	  a	  variant	  with	  BFavg=2500	  has	  posterior	  probability	  of	  association	  of	  2.5%.	  	  
Across	  the	  31	  tier	  1	  loci	  not	  previously	  reported,	  we	  would	  expect	  about	  three	  to	  represent	  
real	  associations.	  	  However,	  this	  computation	  relies	  crucially	  on	  the	  prior	  odds	  of	  
association.	  	  If	  associated	  variants	  are	  tagged	  over	  more	  of	  the	  genome	  (say	  around	  0.01cM)	  
and	  more	  regions	  of	  the	  genome	  (say	  50	  or	  more)	  are	  associated,	  giving	  a	  prior	  odds	  of	  
around	  one	  in	  20,000,	  a	  variant	  with	  BFavg=2500	  has	  a	  posterior	  probability	  of	  association	  of	  
11%,	  and	  we	  would	  expect	  about	  8	  of	  the	  novel	  31	  loci	  to	  be	  true	  associations.	  
Prior	  sensitivity	  analysis	  
To	  investigate	  the	  sensitivity	  of	  the	  model-­‐averaged	  Bayes	  factor	  to	  the	  choice	  of	  prior,	  we	  
plotted	  the	  ratio	  of	  BFavg	  computed	  under	  modified	  priors	  to	  its	  value	  under	  the	  prior	  used	  in	  
the	  GWAS	  (referred	  to	  here	  as	  the	  BFavg	  ratio)	  for	  the	  32	  tier	  1	  autosomal	  variants	  (Extended	  
Data	  Figure	  5c).	  	  We	  considered	  modifications	  of	  the	  prior	  along	  several	  one-­‐dimensional	  
axes	  of	  variation:	  	  -­‐ The	  prior	  standard	  deviation	  on	  effect	  sizes.	  	  We	  varied	  the	  small-­‐effect	  standard	  
deviation	  from	  0.01	  to	  0.75,	  keeping	  the	  large-­‐effect	  and	  small-­‐effect	  standard	  
deviations	  in	  the	  proportion	  0.75	  :	  0.2.	  -­‐ The	  prior	  weight	  assigned	  to	  additive,	  dominant,	  recessive	  and	  heterozygote	  models.	  	  
For	  each	  model	  we	  varied	  the	  prior	  weight	  from	  0	  to	  1,	  keeping	  prior	  weights	  on	  the	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other	  three	  models	  in	  the	  same	  relative	  proportion.	  	  (Note	  that	  because	  the	  BFavg	  is	  a	  
linear	  combination	  of	  component	  models,	  the	  BFavg	  ratio	  depends	  linearly	  on	  the	  prior	  
weight.)	  -­‐ The	  prior	  weight	  assigned	  to	  fixed,	  correlated,	  independent,	  fixed-­‐structured	  and	  
correlated-­‐structured	  models.	  	  For	  each	  heterogeneity	  model,	  we	  varied	  the	  weight	  
from	  0	  to	  1,	  keeping	  the	  other	  four	  models	  in	  the	  same	  relative	  proportion.	  
We	  quantified	  the	  sensitivity	  to	  the	  prior	  by	  considering	  the	  relative	  change	  in	  BFavg	  
corresponding	  to	  a	  doubling	  of	  each	  prior	  parameter.	  	  Theoretically,	  a	  variant	  showing	  
strong	  evidence	  for	  association	  under	  a	  single	  mode	  of	  inheritance	  or	  heterogeneity	  model,	  
and	  strong	  evidence	  against	  association	  under	  the	  other	  component	  models,	  would	  attain	  a	  
doubling	  of	  BFavg	  for	  a	  doubling	  of	  the	  corresponding	  prior	  parameter.	  	  Some	  variants	  in	  our	  
tier	  1	  list	  came	  close	  to	  this	  value.	  	  Ten	  variants,	  including	  the	  lead	  markers	  in	  the	  GRIK1	  
(rs459370,	  which	  showed	  strong	  evidence	  for	  heterozygote	  model)	  and	  ATP2B4	  (rs4951377,	  
dominant	  model)	  had	  BFavg	  ratio	  greater	  than	  1.9	  for	  doubling	  the	  weight	  on	  the	  preferred	  
mode	  of	  inheritance.	  	  Lead	  markers	  at	  all	  three	  previously	  reported	  loci	  (ATP2B4,	  HBB	  and	  
ABO)	  had	  BF	  ratio	  >	  1.7,	  indicating	  that	  placing	  at	  least	  some	  weight	  on	  nonadditive	  models	  
is	  helpful	  in	  detecting	  loci	  such	  as	  these.	  	  In	  contrast,	  the	  lead	  marker	  at	  FREM3/GYPE	  (black	  
dots	  in	  Extended	  Data	  Figure	  5c)	  was	  among	  a	  group	  of	  SNPs	  for	  which	  the	  evidence	  for	  
association	  remained	  relatively	  constant	  across	  model	  specifications.	  This	  behaviour	  reflects	  
the	  low	  frequency	  of	  rs184895969,	  particularly	  in	  West	  Africa,	  which	  leads	  to	  similar	  levels	  
of	  evidence	  across	  models.	  
We	  note	  that	  the	  effect	  of	  relative	  changes	  in	  the	  Bayes	  factor	  on	  posterior	  probability	  
diminishes	  as	  the	  overall	  evidence	  grows.	  	  This	  is	  because,	  while	  the	  posterior	  odds	  is	  
proportional	  to	  the	  Bayes	  factor,	  probability	  as	  a	  function	  of	  odds	  becomes	  flatter	  as	  the	  
odds	  becomes	  large.	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1 29368501 rs2985337 G A EPB41 0.624 0.182 0.043 2.43E‐05 5.24E‐05 0.676 0.159 0.062 9.95E‐03 1.76E‐02 0.650 0.072 0.056 1.99E‐01 5.57E‐01 0.146 0.030 1.19E‐06 1.91E‐05
1 81387469 rs3956370 T G (no gene in region) 0.211 0.144 0.052 5.64E‐03 7.07E‐03 0.164 0.180 0.079 2.26E‐02 3.21E‐02 0.165 0.113 0.074 1.26E‐01 8.46E‐02 0.144 0.037 1.20E‐04 1.30E‐04
1 176734170 rs12083094 G T PAPPA2 0.690 0.143 0.045 1.62E‐03 2.80E‐03 0.577 0.103 0.059 7.86E‐02 1.25E‐01 0.556 0.183 0.055 7.65E‐04 1.47E‐03 0.145 0.030 1.40E‐06 6.08E‐06
1 203658471 rs4951377 A G ATP2B4 0.691 0.190 0.045 2.70E‐05 1.94E‐05 0.683 0.211 0.063 7.85E‐04 4.46E‐04 0.665 0.080 0.058 1.66E‐01 1.75E‐01 0.163 0.031 1.43E‐07 7.43E‐08
1 238010779 rs10802640 C T RYR2 0.699 ‐0.075 0.048 1.16E‐01 2.28E‐01 0.657 ‐0.244 0.060 4.87E‐05 2.37E‐05 0.613 ‐0.163 0.056 3.55E‐03 1.06E‐02 ‐0.148 0.031 2.17E‐06 1.24E‐05
2 28689261 rs11127155 C A PLB1 0.215 0.236 0.049 1.65E‐06 1.47E‐06 0.107 0.114 0.091 2.10E‐01 2.17E‐01 0.144 ‐0.177 0.078 2.22E‐02 2.90E‐02 0.116 0.038 2.13E‐03 1.54E‐03
2 75881313 rs185074554 T A MRPL19 0.008 ‐0.780 0.314 9.89E‐03 1.01E‐02 0.037 ‐0.780 0.195 2.75E‐05 2.24E‐05 0.031 ‐0.337 0.174 5.09E‐02 5.57E‐02 ‐0.569 0.120 2.06E‐06 8.31E‐07
2 124756492 rs73952402 G A CNTNAP5 0.036 ‐0.472 0.132 2.68E‐04 3.36E‐04 0.047 ‐0.344 0.149 1.95E‐02 1.65E‐02 0.046 ‐0.296 0.140 3.34E‐02 3.09E‐02 ‐0.376 0.081 3.17E‐06 2.01E‐06
3 160381509 rs74954675 A C ARL14 0.067 0.320 0.077 3.11E‐05 2.51E‐05 0.104 0.175 0.091 5.53E‐02 5.83E‐02 0.075 0.277 0.094 3.08E‐03 6.89E‐03 0.264 0.050 1.22E‐07 1.79E‐07
4 143574835 rs149373719 A G INPP4B 0.007 ‐0.870 0.380 1.34E‐02 1.26E‐02 0.029 0.077 0.164 6.41E‐01 5.69E‐01 0.070 ‐0.653 0.123 6.68E‐08 4.03E‐08 ‐0.420 0.096 1.13E‐05 3.08E‐06
4 144698528 rs184895969 C T FREM3 0.007 ‐0.164 0.253 5.17E‐01 5.36E‐01 0.053 ‐0.219 0.140 1.15E‐01 1.23E‐01 0.101 ‐0.512 0.100 2.01E‐07 1.60E‐07 ‐0.389 0.077 5.02E‐07 2.84E‐07
4 145332477 chr4:145332477:D CT C HHIP‐AS1 0.686 ‐0.036 0.045 4.27E‐01 4.12E‐01 0.614 ‐0.057 0.060 3.44E‐01 4.08E‐01 0.652 ‐0.076 0.057 1.82E‐01 1.61E‐01 ‐0.052 0.030 8.39E‐02 8.52E‐02
4 172318311 rs10010825 G A (no gene in region) 0.854 0.060 0.061 3.22E‐01 3.50E‐01 0.785 0.204 0.073 4.77E‐03 7.00E‐03 0.776 0.174 0.066 8.47E‐03 1.55E‐02 0.138 0.038 3.04E‐04 7.21E‐04
5 138070692 rs147140121 C A CTNNA1 0.019 0.363 0.142 9.94E‐03 1.32E‐02 0.043 0.409 0.137 2.74E‐03 4.59E‐03 0.028 0.391 0.147 7.17E‐03 4.03E‐03 0.388 0.082 2.22E‐06 2.28E‐06
6 21706044 rs7759495 G A LINC00340 0.544 ‐0.166 0.043 1.04E‐04 9.92E‐05 0.550 ‐0.125 0.057 2.91E‐02 4.60E‐02 0.560 ‐0.093 0.055 8.99E‐02 8.40E‐02 ‐0.135 0.029 3.53E‐06 4.48E‐06
6 118715741 rs6922949 C T CEP85L 0.067 ‐0.080 0.082 3.31E‐01 4.04E‐01 0.112 ‐0.339 0.097 4.06E‐04 7.36E‐04 0.142 ‐0.324 0.081 5.65E‐05 2.44E‐04 ‐0.239 0.049 1.39E‐06 8.36E‐06
7 85419011 rs9640563 T G (no gene in region) 0.376 0.096 0.043 2.47E‐02 3.06E‐02 0.440 0.125 0.057 2.80E‐02 3.17E‐02 0.410 0.124 0.054 2.09E‐02 2.44E‐02 0.111 0.029 1.11E‐04 1.76E‐04
7 154510935 rs73498006 A G DPP6 0.055 0.456 0.089 1.97E‐07 1.73E‐07 0.060 ‐0.019 0.130 8.85E‐01 8.48E‐01 0.070 0.186 0.109 8.61E‐02 1.13E‐01 0.268 0.061 1.07E‐05 8.67E‐06
7 155511663 rs58969967 A T RBM33 0.322 ‐0.070 0.046 1.24E‐01 1.95E‐01 0.319 0.171 0.061 5.13E‐03 5.17E‐03 0.367 ‐0.220 0.058 1.26E‐04 2.16E‐04 ‐0.052 0.031 9.34E‐02 1.31E‐01
8 74790601 rs73323813 G C UBE2W 0.148 0.168 0.057 2.96E‐03 2.00E‐03 0.123 0.310 0.083 1.65E‐04 2.05E‐04 0.125 0.226 0.080 4.39E‐03 4.07E‐03 0.217 0.040 7.65E‐08 4.89E‐08
8 144811885 rs11994280 G C FAM83H 0.179 0.282 0.053 9.71E‐08 7.01E‐08 0.201 ‐0.091 0.074 2.20E‐01 2.36E‐01 0.145 ‐0.123 0.078 1.15E‐01 1.45E‐01 0.091 0.038 1.66E‐02 9.07E‐03
9 37223751 rs2029647 T C ZCCHC7 0.068 0.202 0.079 1.06E‐02 1.62E‐02 0.119 ‐0.267 0.094 4.51E‐03 1.07E‐02 0.123 ‐0.261 0.085 2.00E‐03 2.26E‐03 ‐0.083 0.049 9.37E‐02 1.19E‐01
9 136132908 chr9:136132908:I T TC ABO 0.316 0.230 0.044 1.64E‐07 4.13E‐07 0.315 0.166 0.061 6.62E‐03 4.61E‐03 0.259 0.251 0.061 3.22E‐05 1.06E‐05 0.219 0.031 1.11E‐12 4.97E‐13
11 5367231 rs186699529 C A OR51B5 0.060 ‐1.686 0.156 7.22E‐38 0.00 0.008 ‐0.572 0.376 1.19E‐01 1.58E‐01 0.000 8.041 60.836 2.71E‐01 4.18E‐01 ‐1.522 0.144 4.07E‐26 8.09E‐34
11 17901734 rs60553645 G A SERGEF 0.064 0.236 0.084 4.70E‐03 3.84E‐03 0.082 0.317 0.100 1.46E‐03 1.51E‐03 0.080 0.251 0.096 8.79E‐03 1.14E‐02 0.264 0.053 7.79E‐07 7.91E‐07
11 119347363 rs57030511 G A LOC100499227 0.176 ‐0.127 0.056 2.34E‐02 2.03E‐02 0.133 ‐0.134 0.087 1.22E‐01 1.22E‐01 0.155 ‐0.243 0.079 2.09E‐03 1.07E‐03 ‐0.158 0.040 8.76E‐05 4.71E‐05
12 78947679 rs1717399 T A (no gene in region) 0.426 0.166 0.042 5.97E‐05 7.19E‐05 0.568 0.144 0.058 1.28E‐02 1.56E‐02 0.568 0.093 0.055 8.61E‐02 1.86E‐01 0.141 0.029 9.43E‐07 3.44E‐06
12 128825437 chr12:128825437:I T TTCTTTCTC TMEM132C 0.331 ‐0.139 0.046 2.41E‐03 5.11E‐03 0.355 ‐0.172 0.063 6.48E‐03 7.04E‐03 0.326 ‐0.132 0.061 3.05E‐02 2.19E‐02 ‐0.145 0.032 4.67E‐06 7.68E‐06
16 87697264 rs8058906 C T JPH3 0.305 ‐0.242 0.048 4.92E‐07 4.27E‐06 0.384 ‐0.049 0.060 4.17E‐01 4.09E‐01 0.383 ‐0.035 0.055 5.17E‐01 2.95E‐01 ‐0.124 0.031 6.23E‐05 6.09E‐05
18 27533505 rs57224554 C T (no gene) 0.016 0.647 0.152 1.37E‐05 1.34E‐05 0.051 ‐0.545 0.151 2.25E‐04 1.63E‐04 0.041 ‐0.252 0.144 7.95E‐02 9.36E‐02 ‐0.061 0.086 4.80E‐01 5.58E‐01
21 31350941 rs459370 T C GRIK1 0.593 ‐0.096 0.042 2.32E‐02 3.72E‐02 0.472 ‐0.068 0.057 2.36E‐01 3.81E‐01 0.522 0.045 0.052 3.94E‐01 5.47E‐01 ‐0.047 0.029 9.78E‐02 1.30E‐01
21 41617062 rs58205780 T C DSCAM 0.136 ‐0.191 0.063 2.24E‐03 3.04E‐03 0.138 ‐0.121 0.084 1.51E‐01 1.44E‐01 0.138 ‐0.263 0.081 1.19E‐03 1.30E‐03 ‐0.193 0.043 6.56E‐06 7.83E‐06
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